Company Insights

CRDF supplier relationships

Explore interactive graphBrowse insights index
CRDF supplier relationship map

Cardiff Oncology (CRDF): supplier relationships, contracts and what they mean for investors

Cardiff Oncology is a clinical‑stage biotech that develops PLK1‑directed oncology drugs, principally onvansertib, and monetizes through licensed intellectual property and clinical-stage asset advancement toward partnership or commercialization. Revenue today is negligible; value extraction is driven by successful clinical execution, licensing leverage and capital markets access, while operating risk is concentrated in clinical and vendor dependencies. For investors and operators evaluating supplier posture, the supplier map is small but strategically important — these relationships influence trial execution, investor communications and capital flexibility. Learn more about how we map supplier exposure at https://nullexposure.com/.

How to read Cardiff’s supplier footprint in one sentence

Cardiff outsources clinical execution and investor/media communications, retains licensed rights to core assets, and relies on banking partners for financing tools — a supplier profile typical of clinical‑stage biotech where third parties are operationally critical.

Supplier and service provider map: who does what, with proof

Below I cover every named relationship in the available results; each entry is a concise investor‑oriented summary with a source reference.

Pfizer — clinical execution partner for CRDF‑004

Pfizer provides clinical execution support for Cardiff’s randomized Phase 2 trial CRDF‑004 and historically supplied clinical development infrastructure through Pfizer Ignite to run onvansertib mCRC studies. According to a March 2026 8‑K summary reported by StockTitan, Pfizer is providing clinical execution for CRDF‑004, and a 2025 Zacks report notes Pfizer Ignite’s role in Cardiff’s development in 2023. (StockTitan 8‑K filing summary, March 2026; Zacks initiating coverage, FY2025)

Jefferies — financing channel (ATM facility)

Cardiff has access to an at‑the‑market (ATM) facility with Jefferies that supplements registered offerings at low incremental cost, giving management a flexible equity issuance tool to fund operations. This was identified in a 2025 Zacks coverage piece describing the company’s banking relationships and financing options. (Zacks initiating coverage, FY2025)

Sidoti — investor conference platform

Management presented and held one‑on‑one meetings at Sidoti’s Year‑End Virtual Investor Conference in December 2025, a channel for investor engagement and visibility. The company announced participation in a GlobeNewswire release dated December 2025. (GlobeNewswire press release, December 2025)

Astr Partners / astr partners — investor relations contact

Astr Partners (styled in press releases as Astr Partners or astr partners) serves as Cardiff’s investor relations contact for multiple corporate updates and conference appearances, providing ongoing IR support. Investor contact listings with Candice Masse appear across the company press releases in 2025–2026. (GlobeNewswire and SahmCapital press releases, FY2025–FY2026)

Lyra Strategic Advisory — media relations and PR support

Lyra Strategic Advisory is Cardiff’s media relations firm, repeatedly listed as the media contact (Amy Bonanno) across multiple press announcements in late 2025 and early 2026, indicating a retained PR relationship for trial results and corporate updates. (GlobeNewswire press releases, November–December 2025; January 2026)

Gilmartin Group — investor communications for clinical data release

Gilmartin Group was listed as an investor contact for the July 2025 press release announcing positive randomized Phase 2 data for onvansertib, signaling a role in capital markets outreach around clinical readouts. (GlobeNewswire press release, July 29, 2025)

Taft Communications (RF|Binder) — media contact on trial results

Taft Communications, a division of RF|Binder, was named as a media contact in the July 2025 clinical data release, supporting dissemination of trial results to broader media channels. (GlobeNewswire press release, July 29, 2025)

Operating constraints and what they tell investors

The company‑level constraint signals in filings and releases give a clear picture of Cardiff’s contracting posture and operational risks.

  • Licensing is foundational: Cardiff licensed onvansertib from Nerviano Medical Sciences (NMS) under a March 13, 2017 agreement and holds an Exclusive Patent License from MIT for combination therapy patents (September 19, 2018). These licenses establish Cardiff’s exclusive development rights and are core to its value creation strategy. (Company license descriptions in corporate filings)

  • Supplier relationships are operationally critical: The company explicitly flags that supply‑chain or contractor cybersecurity incidents at clinical sites, subcontractors or business partners could materially impact operations, identifying supplier delivery as a critical risk vector rather than an administrative detail. (Company risk disclosures)

  • Supplier role is largely as service provider and active: Cardiff contracts third‑party service providers for clinical execution, IT/program management and security evaluations — the company describes these relationships as active service engagements with independent audits and consulting for controls, indicating routine third‑party oversight. (Company disclosures about third‑party engagements)

Collectively, these constraints show a contracting posture anchored in licensing rights, active outsourcing of clinical and communications functions, and high operational concentration where vendor failure would be critical.

Investment implications — what investors and operators should watch

Cardiff’s supplier map produces a compact set of investment levers and exposures.

  • Clinical execution risk is concentrated. Pfizer’s role in CRDF‑004 means trial timelines and data quality are materially tied to an external clinical execution partner; successful readouts convert licensing value into deal leverage. Strength of clinical partners is therefore a primary value driver.

  • Capital flexibility is enhanced but dilutive. Access to an ATM with Jefferies provides liquidity optionality to fund operations without a single large registered offering, but repeated use will dilute existing shareholders; monitor ATM usage and dilution cadence. (Zacks, FY2025)

  • Communications and disclosure are outsourced to professional IR/PR. Astr Partners, Lyra Strategic Advisory, Gilmartin and Taft are the visible investor/media stack — consistent external communications reduce execution risk in market messaging but concentrate message control in retained firms. Watch for any changes in IR/PR roster around critical data releases.

  • Cybersecurity and third‑party controls are pivotal. The company explicitly calls out the materiality of vendor cybersecurity incidents; investors should seek evidence of vendor oversight, penetration testing schedules, and contractual indemnities where available.

If you want a concise supplier risk brief tailored to your model portfolio, see how we build supplier risk profiles at https://nullexposure.com/.

Tactical monitoring checklist for the next 12 months

For investors focusing on premium finance or partnership value, prioritize these signals: Pfizer’s operational updates on CRDF‑004, any Jefferies ATM utilization notices, and press releases or IR materials distributed via Astr Partners/Lyra/Gilmartin/Taft around clinical data or financing. These items will directly move perceived asset value and funding runway.

Bottom line and next steps

Cardiff runs a lean, outsourced operating model built on licensed IP and externally delivered clinical execution. That creates asymmetric upside if trials succeed, and asymmetric operational risk if key vendors underperform or if cybersecurity issues arise. For dealmakers and risk managers, the two most material relationships to watch are clinical service execution (Pfizer) and financing channels (Jefferies ATM), with investor relations and media firms shaping market response to results.

If you want ongoing monitoring of Cardiff’s vendor and supplier signals, or a bespoke exposure report, visit https://nullexposure.com/ for engagement options.